BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy

The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first

Roche secures CE mark for groundbreaking Vaginitis test that promises accurate diagnosis

Roche says its new assay “resolves this challenge by delivering accurate and specific results

Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients

The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines

Novo Nordisk completes acquisition of Akero Therapeutics

Akero became a wholly owned subsidiary of Novo Nordisk

Croda strikes strategic deal with Amino to boost global supply of high-purity amino acids

The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities

Lilly to invest $6 billion in Huntsville manufacturing hub

The new site will produce next-generation synthetic medicine active pharmaceutical ingredients

Lilly moves forward with $3.56-per-share acquisition of Adverum

Roche’s Columvi combo doubles survival in hard-to-treat lymphoma

Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment

Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected